Search

Displaying results 1121 - 1130 of 10000 in total
  1. Drug

    Cupric oxide

    go.drugbank.com/drugs/DB11134
    Approved

    Cupric oxide may be found in over-the-counter vitamin-mineral supplements as a source of [DB09130]. The mean daily dietary intake of copper in adults ranges between 0.9 and 2.2 mg [L2422]. … They may also be produced from electronic wastes. Cupric oxide poses potential health and environmental concern due to toxic and mutagenic particles generating reactive oxygen species [A32656].

    Mixtures: Vinate AZ, Folitin-Z
  2. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.

    Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-
  3. Drug

    Lumiracoxib

    go.drugbank.com/drugs/DB01283
    ApprovedWithdrawn

    Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). … New Zealand and Canada have also followed suit in recalling the drug.

    Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal
  4. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.

  5. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    It is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.

  6. Drug

    Dronedarone

    go.drugbank.com/drugs/DB04855
    ApprovedInvestigational

    [A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems. … It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease.

    Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide
  7. Drug

    Clonazepam

    go.drugbank.com/drugs/DB01068
    ApprovedIllicitInvestigational

    Now available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. … [FDA Label][A175438,A175441,L5572,F3763,F3787,F3796] Since being first patented in 1960 and then released for sale from Roche in the US in 1975,[T469,T472] clonazepam has experienced a storied history

  8. Drug

    Citrulline

    go.drugbank.com/drugs/DB00155
    InvestigationalNutraceutical

    It is also produced from arginine as a by-product of the reaction catalyzed by NOS family. Its name is derived from citrullus, the Latin word for watermelon, from which it was first isolated.

    Synonyms: N5-carbamoylornithine, N5-Carbamoyl-L-ornithine
  9. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221]. … Alternatively, although talimogene laherparepvec also enters healthy cells, it is not designed to multiply inside them [L2221].

  10. Drug

    Bexagliflozin

    go.drugbank.com/drugs/DB12236
    ApprovedInvestigational

    Its use is not recommended in patients with type 1 diabetes since it may increase their risk of diabetic ketoacidosis.[L44758] … [A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.